Hakan Goker
Direttore/Membro del Consiglio presso Asceneuron SA
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Kevin Weeks | M | - |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | - |
Gerald McMahon | M | 69 |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | 2 anni |
Christoph Wiessner | M | - |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | 12 anni |
Risto Arvo Sakari Lammintausta | M | - |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | 11 anni |
Cheryl Zimberlin | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 8 anni |
Paul Workman | M | 72 |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | - |
Ryan Schubert | M | - |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | 4 anni |
Catherine Pickering | M | - |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | - |
Venkat Reddy | M | - |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | 4 anni |
Lars van der Veen | M | - |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | 7 anni |
Katherine Warner | M | - |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | - |
Joey Mason | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 6 anni |
Roel Bulthuis | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands.
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | 8 anni |
Anthony Kouzarides | M | 66 |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | 9 anni |
Barclay Phillips | M | 61 |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | 4 anni |
Michael Solomon | M | 54 |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | 7 anni |
Jordi Ahnert | M | - |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | - |
Tony Chang | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 8 anni |
Keno Gutierrez | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 7 anni |
Laurent Massuyeau | M | - |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | - |
Christian Schubert | M | - |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | - |
Tim Edwards | M | - |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | 9 anni |
Cheryl Doreen Zimberlin | F | 38 |
Outrun Therapeutics Ltd.
Outrun Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Outrun Therapeutics Ltd. is a British biotechnology company founded in 2019 that develops a platform for drug discovery. | - |
Owen Lozman | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 6 anni |
Therese Maria Liechtenstein | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 6 anni |
Richard Castro | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | - |
Lucy E Wallace | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 6 anni |
Christopher O’Donnell | M | 55 |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | - |
Alberto Libanori | M | 35 |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 5 anni |
Bauke Anninga | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 5 anni |
Mujahid Mohammad | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 5 anni |
Satpal Singh Virdee | M | 48 |
Outrun Therapeutics Ltd.
Outrun Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Outrun Therapeutics Ltd. is a British biotechnology company founded in 2019 that develops a platform for drug discovery. | - |
Anique ter Braake | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 4 anni |
Christian Uhrich | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 3 anni |
Christopher Roberts | M | 55 |
Outrun Therapeutics Ltd.
Outrun Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Outrun Therapeutics Ltd. is a British biotechnology company founded in 2019 that develops a platform for drug discovery. | - |
Jeffrey Bernard Moore | M | 59 |
Outrun Therapeutics Ltd.
Outrun Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Outrun Therapeutics Ltd. is a British biotechnology company founded in 2019 that develops a platform for drug discovery. | - |
Robert Merrick Haigh | M | 64 |
Outrun Therapeutics Ltd.
Outrun Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Outrun Therapeutics Ltd. is a British biotechnology company founded in 2019 that develops a platform for drug discovery. | - |
Christian Haass | M | - |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | - |
Adam Boxer | M | - |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | - |
Michael Ross | M | 75 |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | - |
Sebastian Schöfer | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 7 anni |
Carmen Gallo Alvarez | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 8 anni |
Henrijette Richter | M | 53 |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | - |
Joanna Horobin | M | 69 |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | 4 anni |
Michael G. Moore | M | - |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | 6 anni |
Elaine Jones | M | 69 |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | - |
Lauri Kangas | M | - |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | - |
Stéphane Verdood | M | - |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | - |
Diego Braguglia | M | 58 |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | - |
Viktor Drvota | M | 59 |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | - |
Mark R.L. Krul | M | - |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | 7 anni |
Deborah Harland | M | 64 |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | - |
Anja Koenig | M | 54 |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | - |
William Marshall | M | 60 |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | - |
Claus Asbjørn Andersson | M | 56 |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | 5 anni |
Michael Clayman | M | 72 |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | 5 anni |
Kira Wahlstedt-Lindström | F | - |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | - |
Catherine Moukheibir | F | 64 |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | 3 anni |
Mike Dial | M | - |
Ribometrix, Inc.
Ribometrix, Inc. Pharmaceuticals: MajorHealth Technology Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC. | - |
Christine Martin | M | - |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | - |
Bobby G. Soni | M | 53 |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | - |
Søren Møller | M | 56 |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | - |
Edward Kliphuis | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 8 anni |
Matthew Foy | M | - |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | 9 anni |
Sakae Asanuma | M | 57 |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | - |
Eric Yuen | M | - |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | 5 anni |
Jeanne Bolger | M | - |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | - |
Vanessa Malier | F | 51 |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | - |
Pasi Koskimies | M | - |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | - |
Barbara Angehrn Pavik | F | 50 |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Zina Affas | M | - |
Atlas Venture LLP
Atlas Venture LLP Investment ManagersFinance Atlas Venture LLP is the London office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in Paris and Munich, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The London office was established in 1986. The group manages a range of venture capital funds. | - |
David Festus Charles Moffat | M | - |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | 8 anni |
Anker Gunvald Lundemose | M | 63 |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | - |
Yoni Blau | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 1 anni |
Søren Bregenholt | M | 53 |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | - |
Frederic Geoffrey Albert Destin | M | 52 |
Atlas Venture LLP
Atlas Venture LLP Investment ManagersFinance Atlas Venture LLP is the London office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in Paris and Munich, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The London office was established in 1986. The group manages a range of venture capital funds. | 4 anni |
Pia Michel | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 1 anni |
Javier Nunez-Vicandi | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 1 anni |
Javier Nunez | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 1 anni |
Sara Torrecilla | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 1 anni |
Joy Faucher | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 1 anni |
Amanda Stenbaek | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 1 anni |
philip Stanley | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | - |
Xiaotang Lu | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 1 anni |
Lisa Strittmatter | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | - |
Dougal Adamson | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | - |
Kevin Lee | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | - |
Katharina Freyer | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | - |
Philip Austin | M | - |
Atlas Venture LLP
Atlas Venture LLP Investment ManagersFinance Atlas Venture LLP is the London office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in Paris and Munich, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The London office was established in 1986. The group manages a range of venture capital funds. | 2 anni |
Marcel Deken | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | - |
João Ribas | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 1 anni |
Etienne Daher | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | - |
Anna Chase | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 1 anni |
Nadine Sobotzki | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 2 anni |
Pieter Jeroen Bakker | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 2 anni |
Clemens Lakner | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 2 anni |
Arnaud Autret | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 3 anni |
Andreas Jurgeit | M | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 2 anni |
Jasper Bos | M | 49 |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | 5 anni |
Laura Obenauer | F | - |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Paesi Bassi | 41 | 41.00% |
Regno Unito | 23 | 23.00% |
Svizzera | 19 | 19.00% |
Finlandia | 9 | 9.00% |
Stati Uniti | 9 | 9.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Hakan Goker
- Contatti personali